

Table SI. Symptoms and hypotheses of TSW according to all respondents, and stratified by hospital setting and TSW in differential diagnosis

	All respondents	Hospital setting		P-value _a	Has had TSW in differential diagnosis		P-value _a
Symptoms	N=156, n (%)						
		Academic N=32, n (%)	Non-academic N=101, n (%)		Yes N=46, n (%)	No N=110, n (%)	
Erythema	100 (64.1)	19 (59.4)	65 (64.4)	0.611	39 (84.8)	61 (55.5)	<0.001
Burning/painful/stinging	94 (60.3)	17 (53.1)	60 (59.4)	0.531	32 (69.6)	62 (56.4)	0.124
Oozing and crusting	50 (32.1)	12 (37.5)	32 (31.7)	0.542	11 (23.9)	39 (35.5)	0.159
Papulopustular lesions	47 (30.1)	7 (21.9)	37 (36.6)	0.122	22 (47.8)	25 (22.7)	0.002
Desquamation and xerosis cutis	48 (30.8)	8 (25.0)	30 (29.7)	0.608	12 (26.1)	36 (32.7)	0.413
Pruritus	40 (25.6)	10 (31.3)	22 (21.8)	0.275	12 (26.1)	28 (25.5)	0.934
Edema	30 (19.2)	5 (15.6)	20 (19.8)	0.598	8 (17.4)	22 (20.0)	0.706
Skin infections	18 (11.5)	2 (6.3)	12 (11.9)	0.517 _b	6 (13.0)	12 (10.9)	0.704
Other	10 (6.4)	4 (12.5)	5 (5.0)	0.218 _b	3 (6.5)	7 (6.4)	1.000
Not sure	43 (27.6)	10 (31.3)	28 (27.7)	0.700	4 (8.7)	39 (35.5)	<0.001
Hypotheses	N=148, n (%)						
		Academic N=30, n (%)	Non-academic N=98, n (%)		Yes N=45, n (%)	No N=103, n (%)	
Undertreatment of underlying skin disease	78 (52.7)	18 (60.0)	54 (55.1)	0.636	20 (44.4)	58 (56.3)	0.183
Adverse effect of TCS use	57 (38.5)	8 (26.7)	42 (42.9)	0.112	29 (64.4)	28 (27.2)	<0.001
TSW does not exist	26 (17.6)	12 (40.0)	13 (13.3)	0.001	0 (0)	26 (25.2)	<0.001
TSW is a clinical entity	18 (12.2)	1 (3.3)	11 (11.2)	0.194	10 (22.5)	8 (7.8)	0.013
Other	23 (15.5)	3 (10.0)	17 (17.3)	0.332	11 (24.8)	12 (11.7)	0.048
Not sure	27 (18.2)	4 (13.3)	17 (17.8)	0.603	6 (13.3)	21 (20.4)	0.307

Respondents could select multiple symptoms/hypotheses out of the answer options. Frequencies and percentages of respondents are shown.

a. Frequencies between groups are compared per symptom/hypothesis using the Chi-squared test.

b. Frequencies between groups are compared per symptom/hypothesis using the Fischer's exact test

TCS, topical corticosteroids; TSW, topical steroid withdrawal.

Table SII. Treatment options of TSW according to all respondents, and stratified by hospital setting and TSW in differential diagnosis

	All respondents	Hospital setting		P-value _a	Has had TSW in differential diagnosis		P-value _a
Treatment options	N=150, n (%)						
		Academic N=31, n (%)	Non-academic N=98, n (%)		Yes N=45, n (%)	No N=105, n (%)	
Other topical immunomodulators	117 (78)	23 (74.2)	86 (87.8)	0.088 _b	35 (77.8)	82 (78.1)	0.966
Reinitiating TCS, subsequently tapering	104 (69.3)	24 (77.4)	65 (66.3)	0.244	33 (73.3)	71 (67.6)	0.487
Non-drug treatments	84 (56.0)	13 (41.9)	61 (62.2)	0.046	27 (60.0)	57 (54.3)	0.518
Psychological support	68 (45.3)	15 (48.4)	46 (46.9)	0.888	19 (42.4)	49 (46.7)	0.616
Systemic immunosuppressant	66 (44.0)	17 (54.8)	48 (49.0)	0.570	18 (40.0)	48 (45.7)	0.518
UV-therapy	41 (27.3)	6 (19.4)	31 (31.6)	0.188	12 (26.7)	29 (27.6)	0.905
Antibiotics	36 (24.0)	5 (16.1)	30 (30.6)	0.114	13 (28.9)	23 (21.9)	0.359
Prednisolone	21 (14.0)	5 (16.1)	13 (13.3)	0.765 _b	5 (11.1)	16 (15.2)	0.504
Antihistamines	14 (9.3)	0 (0.0)	12 (12.2)	0.069 _b	4 (8.9)	10 (9.5)	1.000 _b
Keeping TCS ceased	10 (6.7)	5 (16.1)	5 (5.1)	0.060 _b	6 (13.3)	4 (3.8)	0.066 _b
Non-conventional	7 (4.7)	1 (3.2)	4 (4.1)	1.000 _b	5 (11.1)	2 (1.9)	0.026 _b
(Neuropathic) pain medication	1 (0.7)	1 (3.2)	0 (0)	0.240 _b	0 (0)	1 (1.0)	1.000 _b
Other	14 (9.3)	1 (3.2)	7 (7.1)	0.679 _b	5 (11.1)	9 (8.6)	0.760 _b

Respondents could select multiple treatment options out of the answer options. Frequencies and percentages of respondents are shown.

a. Frequencies between groups are compared per treatment option using the Chi-squared test.

b. Frequencies between groups are compared per treatment option using the Fischer's exact test

TCS, topical corticosteroids; UV, ultraviolet, TSW, topical steroid withdrawal

Table SIII. Risk factors and hypotheses of TSW according to all respondents, and stratified by hospital setting and TSW in differential diagnosis

	All respondents		Hospital setting				P-value	Had TSW in differential diagnosis				P-value
Risk factors	N=158											
			Academic N=32		Non-academic N=102			Yes N=46		No N=112		
	Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)		Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)	
Potent TCS use	1.9 (1.1)	54 (34.2)/ 56 (35.4)	1.4 (1.3)	9 (28.1)/ 18 (56.3)	1.9 (1.0)	35 (34.3)/ 31 (30.4)	0.026	2.5 (0.8)	27 (58.7)/ 6 (13.0)	1.6 (1.1)	27 (24.1)/ 50 (44.6)	<0.001
Long-term frequent TCS use	2.2 (1.1)	75 (47.5)/ 38 (24.1)	1.7 (1.3)	11 (34.1)/ 14 (43.8)	2.3 (1.0)	50 (49.0)/ 20 (19.6)	0.023	2.8 (0.7)	32 (69.6)/ 1 (2.2)	2.0 (1.1)	43 (38.4)/ 37 (33.0)	<0.001
TCS use on face or genitals	1.9 (1.1)	54 (32.9)/ 56 (35.4)	1.5 (1.3)	9 (28.1)/ 16 (50.0)	2.0 (1.0)	33 (32.4)/ 32 (31.4)	0.044	2.5 (1.0)	26 (56.5)/ 8 (17.4)	1.7 (1.1)	26 (32.2)/ 48 (42.9)	<0.001
Abruptly stop TCS use	2.6 (1.1)	100 (63.3)/ 23 (14.6)	2.3 (1.2)	17 (53.1)/ 8 (25.0)	2.7 (1.1)	66 (64.7)/ 13 (12.7)	0.234	3.0 (0.9)	36 (78.3)/ 3 (6.5)	2.5 (1.2)	64 (57.1)/ 20 (17.9)	0.023
Hypotheses	N = 152											
			Academic N=31		Non-academic N=100			Yes N=45		No N=107		
	Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)		Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)	
Flaring underlying skin condition	3.2 (0.9)	123 (80.9)/ 4 (2.6)	3.4 (0.8)	19 (61.3)/ 5 (16.1)	3.1 (0.8)	80 (80.0)/ 2 (2.0)	0.045	3.0 (0.8)	35 (77.8)/ 2 (4.4)	3.3 (0.8)	88 (82.2)/ 2 (1.9)	0.033
(Worsening) adverse effects TCS	2.7 (0.9)	106 (69.7)/ 16 (10.5)	2.6 (1.0)	19 (61.3)/ 5 (16.1)	2.9 (0.8)	80 (80.0)/ 5 (5.0)	0.046	2.6 (0.9)	30 (66.7)/ 8 (17.8)	2.8 (0.9)	76 (71.0)/ 8 (7.5)	0.345
Contact allergy TCS	2.2 (1.1)	59 (38.8)/ 37 (24.3)	1.7 (1.0)	6 (19.4)/ 10 (32.3)	2.3 (0.9)	51 (51.0)/ 20 (20.0)	0.004	2.0 (0.9)	13 (28.9)/ 13 (28.9)	2.2 (1.0)	46 (43.0)/ 24 (22.0)	0.128

Skin infection	2.0 (1.0)	55 (36.2)/ 49 (32.2)	1.5 (1.1)	7 (22.6)/ 15 (48.4)	2.1 (1.0)	41 (41.0)/ 29 (29.0)	0.010	2.0 (0.9)	15 (33.3)/ 15 (33.3)	2.0 (1.0)	40 (37.4)/ 34 (31.8)	0.739
Rebound vaso- dilatation	2.6 (0.8)	97 (63.8)/ 10 (6.6)	2.6 (1.0)	18 (58.1)/ 5 (16.1)	2.7 (0.7)	71 (71.0)/ 5 (5.0)	0.440	2.7 (0.7)	29 (64.5)/ 2 (4.4)	2.6 (0.8)	68 (63.6)/ 8 (7.5)	0.645
Other mechanism	1.9 (0.7)	22 (14.5)/ 33 (21.7)	1.8 (0.9)	5 (16.1)/ 10 (32.3)	1.9 (0.7)	12 (12.0)/ 21 (21.0)	0.494	2.1 (0.6)	11 (24.1)/ 4 (8.9)	1.8 (0.7)	11 (10.3)/ 29 (27.1)	0.003

Respondents scored statements regarding risk factors and hypotheses for TSW with a 5-point Likert scale (strongly disagree = 0, disagree = 1, neutral = 2, agree = 3, strongly agree = 4).

Means (SD) are presented and are categorized into three groups: disagree (0-1.4), neutral (1.5-2.4), and agree (2.5-4) to improve comprehensibility of the outcomes. Percentages of respondents agreeing and disagreeing are shown as well. Mean scores on the Likert scale between groups are compared per statement using Mann Whitney U-test.

TCS, topical corticosteroids; TSW, topical steroid withdrawal

Table SIV. Statements of attitudes towards TSW of all respondents, and stratified by hospital setting and TSW in differential diagnosis

	All respondents		Hospital setting				P-value	Had TSW in differential diagnosis				P-value
Attitudes	N = 118											
			Academic N=30		Non-academic N=98			Yes N=45		No N=103		
	Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)		Mean (SD)	Agree (%)/ disagree (%)	Mean (SD)	Agree (%)/ disagree (%)	
More cautious prescribing TCS	1.4 (1.1)	25 (16.9)/ 92 (62.2)	0.9 (1.2)	4 (13.3)/ 23 (76.7)	1.4 (1.1)	18 (18.4)/ 64 (65.3)	0.011	1.8 (1.0)	8 (17.8)/ 20 (44.4)	1.2 (1.1)	17 (16.5)/ 72 (69.9)	0.001
Rather not see TCS refusing patients	1.6 (1.0)	36 (24.2)/ 84 (56.8)	2.2 (1.1)	16 (53.3)/ 11 (36.7)	1.4 (1.0)	18 (18.4)/ 61 (62.2)	0.001	1.2 (1.0)	5 (11.1)/ 31 (68.9)	1.7 (1.1)	31 (30.1)/ 53 (51.5)	0.009
Patch tests are indicated	2.0 (0.9)	51 (34.5)/ 55 (37.2)	1.8 (1.1)	7 (23.3)/ 10 (33.3)	2.0 (0.8)	27 (27.6)/ 26 (26.5)	0.363	1.9 (0.9)	9 (20.0)/ 16 (35.6)	2.0 (0.9)	26 (25.2)/ 26 (25.2)	0.294
Biopsies are indicated	1.5 (0.8)	15 (10.1)/ 75 (50.7)	1.2 (0.9)	1 (3.3)/ 17 (56.7)	1.5 (0.8)	11 (11.2)/ 52 (53.1)	0.132	1.4 (0.7)	1 (2.2)/ 23 (51.1)	1.5 (0.9)	14 (13.6)/ 52 (50.5)	0.788
More likely to start systemic treatment	2.0 (0.9)	51 (34.5)/ 55 (37.2)	2.0 (1.1)	14 (46.7)/ 11 (36.7)	1.9 (0.9)	33 (33.7)/ 39 (39.8)	0.544	2.0 (0.9)	14 (31.1)/ 15 (33.3)	2.0 (1.0)	37 (35.9)/ 40 (38.8)	0.902
Psychologic-al support can be of importance	3.0 (0.7)	115 (77.7)/ 2 (1.4)	3.2 (0.7)	26 (86.7)/ 4 (13.3)	2.9 (0.7)	73 (74.5)/ 2 (2.0)	0.032	2.8 (7.2)	30 (66.7)/ 1 (2.2)	3.0 (0.7)	85 (82.5)/ 1 (1.0)	0.044
Confident addressing concerns about TCS and TSW	2.6 (0.9)	92 (62.2)/ 21 (14.2)	2.4 (1.3)	17 (56.7)/ 7 (23.3)	2.6 (0.8)	63 (64.3)/ 12 (12.2)	0.722	2.6 (0.9)	30 (66.7)/ 6 (13.3)	2.6 (1.0)	62 (60.2)/ 15 (14.6)	0.554
Confident treating TSW	2.1 (1.1)	63 (42.6)/ 43 (29.1)	1.8 (1.2)	10 (33.3)/ 12 (40.0)	2.3 (1.0)	46 (46.9)/ 21 (21.4)	0.056	2.5 (1.1)	26 (57.8)/ 8 (17.8)	2.0 (1.1)	37 (35.9)/ 35 (34.0)	0.006

Respondents scored statements regarding attitudes towards TSW with a 5-point Likert scale (strongly disagree = 0, disagree = 1, neutral = 2, agree = 3, strongly agree = 4). Means (SD) are presented and are categorized into three groups: disagree (0-1.4), neutral (1.5-2.4), and agree (2.5-4) to improve comprehensibility of the outcomes. Percentages of respondents agreeing and disagreeing are shown as well. Mean scores on the Likert scale between groups are compared per statement using Mann Whitney U-test.

TCS, topical corticosteroids; TSW, topical steroid withdrawal